Why Is Sarepta Therapeutics Stock Exploding Today?

Promising Early Data From Sarepta ProgramsSarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.Early results from the Phase 1/2 trials showed dose-dependent muscle exposure and favorable tolerability, reinforcing confidence in the potential of these investigational treatments.The company highlighted that both SRP- ...